SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is experiencing intense downward pressure, hitting new multi-year lows as investors weigh concerns over China market demand, tariff impacts, and increased competition against a leadership-led turnaround effort. While the community remains dividedwith some viewing the current price as a generational value opportunity and others bracing for further downside toward the $40 levelactive discussions are centered on whether the upcoming earnings report will confirm a stabilization in margins or trigger further selling.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware (RH) is experiencing heightened volatility and intense community debate as investors weigh the company's recent earnings results, persistent tariff risks, and ongoing concerns regarding the luxury housing market. While some market participants are aggressively positioning for a potential short squeeze or recovery driven by leadership changes and long-term expansion plans, others remain skeptical, citing high debt levels and poor consumer demand for high-end furniture.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as the community closely monitors the upcoming 10-K filing and earnings report, with sentiment buoyed by aggressive debt reduction and the stellar performance of major holdings like BW and APLD. Investors are actively discussing the potential for a significant valuation re-rating and short squeeze, viewing the recent clearing of share pledges by the CEO as a major catalyst that could force bearish positions to unwind.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is currently in focus as investors weigh the company's transition from research and development to commercial execution amid increased financial transparency. While some community members remain skeptical regarding the timing of revenue and past management actions, others are actively analyzing recent capital raises and potential ecosystem integrations to gauge the company's position within the rapidly evolving AI photonics landscape.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors digest the commercial launch of Yartemlea following recent FDA approval, with the community actively debating the company's long-term value, revenue potential, and the impact of the partnership with Novo Nordisk. Despite volatility from short interest and options-related pressure, discussions remain focused on upcoming catalysts such as EMA regulatory decisions and the broader outlook for the company's pipeline.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is generating significant community interest driven by its role as a high-speed, low-cost settlement rail, with many participants viewing it as a top-tier asset alongside Bitcoin and Ethereum for institutional adoption. The conversation remains highly active, split between bullish narratives around its ecosystem scalability and traders focusing on opportunistic entries amid ongoing market volatility.

Dave & Buster's Entertainment, Inc. engages in the ownership and operation of entertainment and dining venues under the name Dave & Buster's. It offers a full menu of entrées and appetizers, a selection of alcoholic and non-alcoholic beverages, and an assortment of entertainment attractions centered around playing games and watching live sports and other televised events. The company was founded by David O. Corriveau and James W. Corley in 1982 and is headquartered in Coppell, TX.

Dave & Buster`s Entertainment Inc

Dave & Buster's Entertainment

Dave & Buster's is currently a focal point for investors due to its high short interest and speculative potential for a short squeeze, despite ongoing concerns about its business model and the impact of discretionary spending shifts. The community is actively debating the company's turnaround strategy under new leadership while weighing the risks of its significant debt levels against the possibility of institutional share accumulation.

"What's Updog?" is a Community Led token.

UpDog

UpDog is generating significant buzz as community members rally to drive momentum and advocate for broader retail participation in the memecoin space. Discussions are centered on the token's long-standing presence in the market, with participants actively sharing swap details and engaging in playful, meme-driven social activity.

nCino, Inc. engages in the provision of cloud-based software applications for financial institutions in the United States and internationally. Its nCino Bank Operating System, a tenant cloud platform, digitizes, automates, and streamlines complex processes and workflow, and utilizes data analytics and artificial intelligence and machine learning (AI/ML) to enable financial institutions to onboard new clients, make loans, and manage the entire loan life cycle, open deposit and other accounts, and manage regulatory compliance. The firm's nCino IQ is an application suite that utilizes data analytics and AI/ML to provide its customers with automation and insights into their operations, such as tools for analyzing, measuring, and managing credit risk, as well as to enhance their ability to comply with regulatory requirements. The company was founded by Pierre Naudé in 2011 and is headquartered in Wilmington, NC.

Ncino Inc.

nCino is trending following the announcement of a $100 million accelerated share repurchase program, sparking community discussion about the company's capital allocation strategy and long-term growth potential. Investors are closely monitoring the stock as it navigates a broader fintech sector transition, with debates centering on its ability to leverage AI-driven banking solutions and maintain market share.

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals is trending following positive preliminary efficacy and safety data from its Phase 1b trial of ORIC-944 in combination with androgen receptor inhibitors for prostate cancer. Investors are actively discussing the significance of the company's recent capital raise, its partnership with Pfizer, and the potential for a short squeeze given the high short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>In a mid-stage study, alixorexton demonstrated statistically significant, clinically meaningful and dose-dependent improvements from baseline compared to placebo in wakefulness.</li><li>RBC Capital said the Lilly-Centessa deal highlights large pharma interest in the sleep space and "underscores what could likely be a large indication," which is "favorable" for Alkermes.</li><li>Leerink, who has a ‘Market Perform’ rating on Alkermes shares, opined that the stock could attract interest from large pharma companies seeking a presence in sleep disorders.</li></ul>Shares of Alkermes Plc (ALKS) rallied 15% on Tuesday after pharmaceutical giant Eli Lilly and Company reached an agreement to acquire its peer Centessa for up to $7.8 billion.Centessa is developing a pipeline of orexin receptor 2 (OX2R) agonists to treat excessive daytime sleepiness and disorders of impaired wakefulness. Its lead investigational candidate cleminorexton is under development to treat narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia.Alkermes, meanwhile, is also developing an orexin 2 receptor for narcolepsy called alixorexton. In a mid-stage study, alixorexton demonstrated statistically significant, clinically meaningful and dose-dependent improvements from baseline compared to placebo in wakefulness. Alkermes plans to initiate the alixorexton narcolepsy global phase 3 program in early 2026.<h2 class="st-heading-2">Wall Street Weighs In</h2>RBC Capital said the Lilly-Centessa deal highlights large pharma interest in the sleep space and "underscores what could likely be a large indication," which is "favorable" for Alkermes. The firm, which thinks Alkermes' current share price is undervaluing the orexin program alone given comps, notwithstanding the profitable core business, has an ‘Outperform’ rating and $45 price target on the shares.Leerink, who has a ‘Market Perform’ rating on Alkermes shares, opined that the stock could attract interest from large pharma companies seeking a presence in sleep disorders.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around ALKS stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘normal’ levels.<a href="https://stocktwits.com/symbol/ALKS">ALKS stock</a> has gained 5% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-rallies-in-anticipation-of-upbeat-q1-delivery-numbers-after-america-expansion-efforts/cZE5cWMRIVp">Nio Stock Rallies In Anticipation Of Upbeat Q1 Delivery Numbers After America Expansion Efforts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Alkermes logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes

Alkermes, like Centessa, is also developing an orexin 2 receptor for narcolepsy called alixorexton.

Equity

Alkermes, like Centessa, is also developing an orexin 2 receptor for narcolepsy called alixorexton.


Alkermes (NASDAQ:ALKS) Shares Gap Up - Still a Buy?

Alkermes (NASDAQ:ALKS) Shares Gap Up - Should You Buy...

Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave...

Alkermes plc (NASDAQ:ALKS) Receives Consensus Rating of "Moderate Buy" from Analysts

Alkermes plc (NASDAQ:ALKS - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eighteen brokerages that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have assi...

Tudor Investment Corp ET AL Acquires New Position in Alkermes plc $ALKS

Tudor Investment Corp ET AL acquired a new stake in shares of Alkermes plc (NASDAQ:ALKS - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange...

Why Is Alkermes (ALKS) Down 2.6% Since Last Earnings Report?

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alkermes (NASDAQ:ALKS) Stock Rating Upgraded by Truist Financial

Truist Financial upgraded shares of Alkermes to a "strong-buy" rating in a research note on Wednesday...

Piper Sandler Issues Pessimistic Forecast for Alkermes (NASDAQ:ALKS) Stock Price

Piper Sandler cut their price target on shares of Alkermes from $45.00 to $43.00 and set an "overweight" rating on the stock in a report on Tuesday...

Alkermes CEO Pops Calls 2026 a Really Exciting Year as Orexin Agonists Near Narcolepsy Launch

Alkermes (NASDAQ:ALKS) CEO Richard Pops said the company is entering what he described as a really exciting year as the orexin agonist field moves closer to commercialization in narcolepsy, with...

Holocene Advisors LP Cuts Holdings in Alkermes plc $ALKS

Holocene Advisors LP lowered its stake in Alkermes plc (NASDAQ:ALKS - Free Report) by 13.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange...

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Alkermes plc

iShares Dynamic Equity Active ETF ($BDYN)

Grayscale Bitcoin Trust ETF ($GBTC)

Destiny Tech100 Inc ($DXYZ)

Global X Defense Tech ETF ($SHLD)

The Modern Portfolio Builder. This award honors the fund that makes long-term investing easier, cheaper, or more effective for people who want to "set it and forget it."

ALKS
Alkermes plc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ALKS News

ALKSAlkermes plc